> Vicore Pharma struck a deal to buy INIM Pharma. The takeover will give Vicore control of an experimental inhaled immunomodulatory treatment for idiopathic pulmonary fibrosis and other lung diseases. Release
> iTeos Therapeutics named Scott Chappel, Ph.D., as its CSO. Chappel was a founder and chief technology officer at Surface Oncology. Statement
> A phase 2b trial of Neovacs’ IFNalpha Kinoid in lupus missed its primary efficacy endpoint. But with other measures painting the drug in a better light, Neovacs still plans to move into phase 3. Release
> VarmX raised €12.5 million ($14.6 million) to move its treatment for severe bleeding in patients taking anticoagulants into human testing. Statement
> Sanofi’s Ablynx took a big step toward the European approval of Cablivi, its treatment for acquired thrombotic thrombocytopenic purpura. Release (PDF)
> Abivax posted top-line data from a phase 2a trial of its HIV candidate ABX464. Statement